Satoshi Ide1,2, Hiromasa Hayama3, Yusuke Asai4, Mari Terada1, Hidetoshi Nomoto1,2, Satoshi Kutsuna1, Norio Ohmagari1,2, Yukio Hiroi3. 1. Disease Control and Prevention Center, National Center for Global Health and Medicine. 2. Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University. 3. Department of Cardiology, National Center for Global Health and Medicine. 4. AMR Clinical Reference Center, National Center for Global Health and Medicine.
Abstract
BACKGROUND: Several studies have reported elevated troponin levels in coronavirus disease 2019 (COVID-19) patients, so we investigated myocardial damage by measuring high-sensitivity troponin T (hsTnT) levels and analyzed the relationship with comorbidities.Methods and Results: Of 209 patients who recently recovered from COVID-19, 65% had an elevated hsTnT level that was higher than levels in patients with acute phase infection despite most patients (79%) having a mild illness. The hsTnT levels correlated with disease severity, sex, comorbidities, and ACEi and ARB use. CONCLUSIONS: Myocardial damage occurs in the recovery phase of COVID-19, and its evaluation, regardless of patient age, should be considered.
BACKGROUND: Several studies have reported elevated troponin levels in coronavirus disease 2019 (COVID-19) patients, so we investigated myocardial damage by measuring high-sensitivity troponin T (hsTnT) levels and analyzed the relationship with comorbidities.Methods and Results: Of 209 patients who recently recovered from COVID-19, 65% had an elevated hsTnT level that was higher than levels in patients with acute phase infection despite most patients (79%) having a mild illness. The hsTnT levels correlated with disease severity, sex, comorbidities, and ACEi and ARB use. CONCLUSIONS:Myocardial damage occurs in the recovery phase of COVID-19, and its evaluation, regardless of patient age, should be considered.